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 CD4+CD28null T cells and/or a previous CMV infection and 
IMT or PWV. There was no relation between anti-hHSP60 
and  CD4+CD28null T cells. Increased PWV values suggest 
atherosclerotic damage in patients with AAV. Plaque size, 
as determined by IMT, did not differ.  CD4+CD28null T cells 
are increased in AAV and related to the previous CMV 
infection.
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Introduction
Small vessel vasculitides, such as granulomatosis with pol-
yangiitis (GPA) and microscopic polyangiitis (MPA), are 
strongly associated with ANCA, which are either directed 
to myeloperoxidase (MPO) or proteinase 3 (PR3) [1, 2]. 
These diseases can occur in any organ system, but the res-
piratory tract and the kidneys are most frequently involved. 
Since the introduction of cyclophosphamide and predniso-
lone as the standard treatment, survival has improved dra-
matically from less than 20% at 1 year reported in 1958 [3] 
to at least 60% 5-year survival reported in the past 20 years 
[4].
With prolonged survival, patients may experience the 
long-term sequelae as a result of their vasculitis or its treat-
ment [5–7]. Several studies have shown that in the long-
term follow-up, cardiovascular disease is a major cause 
of mortality in patients with ANCA-associated vasculitis 
(AAV) [8–12]. Furthermore, two studies have shown that 
the annual incidence of myocardial infarction in patients 
with AAV is much higher than in the background popula-
tion [13, 14].
Abstract Previous studies have suggested an increased 
risk for cardiovascular events in antineutrophil cytoplas-
mic antibodies (ANCA)-associated vasculitis (AAV). We 
analyzed the presence of atherosclerotic damage in patients 
with AAV in relation to the presence of  CD4+CD28null T 
cells and antibodies against cytomegalovirus (CMV) and 
human Heat-Shock Protein 60 (hHSP60). In this cross-
sectional study, patients with inactive AAV were com-
pared with healthy controls (HC). Carotid intima-media 
thickness (IMT) and aortic pulse-wave velocity (PWV) 
were measured. In addition,  CD4+CD28null T cells, anti-
CMV, and anti-hHSP60 levels were determined. Forty 
patients with AAV were included. Patients’ spouses were 
recruited as HC (N = 38).  CD4+CD28null T cells are present 
in patients with AAV in a higher percentage (median 3.1, 
range 0.01–85) than in HC (0.28, 0–36, P < 0.0001). No 
significant difference in IMT (mm) between patients and 
controls was detected (mean 0.77 ± standard deviation 0.15 
and 0.73 ± 0.11, respectively, P = 0.20). PWV standardized 
for MAP was increased in AAV patients (9.80 ± 2.50 m/s, 
compared to 8.72 ± 1.68 in HC, P = 0.04). There was a 
strong association between a previous CMV infection and 
the presence and percentage of  CD4+CD28null T cells (0.33 
vs 13.8, P < 0.001). There was no relationship between 
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Atherosclerosis is now widely regarded as an inflam-
matory disease [15], and chronic inflammation seems to 
be important in the progression of atherosclerosis [16, 17]. 
Several studies demonstrated that signs of atherosclerosis 
are apparent in patients with ANCA-associated vasculitis 
(AAV) (reviewed in [11]). Endothelial dysfunction, the ear-
liest stage of atherosclerosis [15], is present during active 
disease in patients with primary systemic vasculitis [18]. 
Furthermore, antibodies against oxidized low-density lipo-
protein (oxLDL), a marker for progression of atheroscle-
rosis [19], are also present in active vasculitis [20]. Anti-
bodies against human Heat-Shock Protein 60 (hHSP60) are 
another marker elevated in both atherosclerosis and vascu-
litis [21, 22].
In patients with unstable angina and myocardial infarc-
tion, the expansion of an unusual subset of  CD4+ T cells 
has been described [23]. The lack of the CD28 molecule 
on these cells suggests repeated antigenic exposure, with 
cytomegalovirus (CMV) and hHSP60 as candidate anti-
gens [24, 25].  CD4+CD28null T cells have acquired a cyto-
toxic phenotype, with expression of perforin, granzyme B, 
and killer cell immunoglobulin-like receptors with loss of 
CD25, and have been shown to be cytotoxic to endothelial 
cells (reviewed in [26]). Interestingly, these cells have been 
found in GPA as well [27]. These T cells may have a role 
in accelerating the atherosclerotic process and/or destabi-
lization of plaques in patients with AAV. Furthermore, an 
increase in IMT was described in patients with rheumatoid 
arthritis who had an increased percentage of  CD4+CD28null 
T cells [28]. In this study, we hypothesized that the pres-
ence of circulating  CD4+CD28null T cells is related to 
the presence of atherosclerotic damage in patients with 
AAV. Furthermore, we hypothesized that antibodies 
against CMV and hHSP60 were related to the presence of 




A cross-sectional study for the presence of accelerated ath-
erosclerosis in patients with AAV.
Study population
All consecutive patients with AAV, who visited the outpa-
tient clinic of our hospital and were willing to participate, 
were included in this study. All patients fulfilled the disease 
definitions for GPA, MPA, and Churg Strauss syndrome as 
proposed by the Chapel Hill Consensus Conference [29]. 
Only patients with inactive disease, as evaluated by the 
Birmingham Vasculitis Activity Score (BVAS) [30], were 
included, since an influence of active disease on the study 
parameters cannot be excluded. However, patients with 
active disease could be included at a later time point when 
disease was in remission. Patients’ spouses were recruited 
as control subjects to have an approximate match for age 
and traditional risk factors. The study was performed in 
accordance with the Declaration of Helsinki. The local 
medical ethics committee (MEtC, university hospital Maas-
tricht, Maastricht) approved of the study. Written informed 
consent was obtained from each person.
All persons were assessed for the traditional risk factors 
for atherosclerosis, previous and current immunosuppres-
sive medication use, and hsCRP.
Laboratory analysis
Anti-CD3, anti-CD4, and anti-perforin monoclonal anti-
bodies were purchased from Becton Dickinson (Franklin 
Lakes, NJ). Anti-CD28 monoclonal antibodies were pur-
chased from Beckman Coulter (Fullerton, CA). The simul-
taneous presence of CD3, CD4, CD28, and perforin was 
evaluated on peripheral blood mononuclear cells using 
four-color flow cytometry (FACSCalibur, BD) and ana-
lyzed using the CellQuest software (BD). The cut-off value 
for percentage of  CD4+CD28null cells in our lab is estab-
lished at 5%. In addition, we tested the presence of CD25 
and killer cell immunoglobulin-like receptors (KIR2DS1 
and KIR2DS2) (BD).
Antibodies against hHSP60 were determined as 
described previously [21]. Results are expressed as anti-
hHSP60 levels in arbitrary units (AU)/mL. The cut-off 
value for this test was previously established at 80 AU/mL 
[21].
Anti-CMV antibodies were determined using the 
axSYM microparticle enzyme immunoassay (Abbott Lab-
oratories, Abbott Park, IL). Results are expressed as anti-
CMV levels in AU/mL. The cut-off value for this test is 
15 AU/mL.
Measurement of the intima-media thickness
The carotid intima-media thickness (IMT) was determined 
in the common carotid artery (CCA) segment 10–20  mm 
proximal to the tip of the flow divider. B-mode images of 
the IMT were acquired for the predefined 10 mm segment 
of the right and left CCA at defined interrogation angles 
using Meijers Arc. The standard images were obtained 
from four angles at each side. The mean IMT of the far 
walls was determined from a single enddiastolic B-mode 
image at each interrogation angle for both the right and 
left CCA with an automated edge-tracking method (M’Ath 
version 2.0.1.0, METRIS, Paris, France). In addition, the 
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largest IMT value in the predefined segment was noted for 
both the left and right CCA.
Measurement of the pulse-wave velocity
Pulse pressure waveforms were recorded from the radial 
and femoral artery using the Complior®SP (Colson, 
France). Pulse-wave velocity was then calculated between 
the carotid and femoral artery (representing the aortic 
tract), and the carotid and radial artery (representing the 
brachial tract). The average of ten measurements was used. 
As PWV is related to blood pressure, we also corrected 
PWV for the mean arterial pressure (MAP) [31]. MAP was 
calculated as diastolic pressure + 0.412 × pulse pressure 
[31]. MAP was standardized at 98, as this was the observed 
MAP in AAV patients (MAP-corrected PWV).
Statistical analyses
All data are presented as mean ± standard deviation unless 
stated otherwise. Continuous data between groups were 
compared using Student’s t test and Mann–Whitney test 
when appropriate. The presence of antibodies in patients 
and controls was compared using Fisher’s exact test, 
obtaining Odds Ratios, and 95% confidence intervals were 
appropriate. Linear regression analysis was performed with 
percentage of  CD4+CD28null T cells and IMT as depend-
ent variables and step-by-step exclusion of non-significant 
independent variables. Univariate analyses were performed 
with GraphPad Prism version 4.00, GraphPad Instat soft-
ware package version 2.04a (both GraphPad Software Inc., 
San Diego, CA). Multivariate analysis was performed with 
SPSS 22.0 (IBM Corporation, New York, NY). A two-




Forty patients with AAV and 38 healthy controls (HC) 
were included. Mean age was 56.4 ± 10.5 in patients and 
54.4 ± 9.7 in HC. Fifty-five percent of the patients were 
male compared to 45% of HC. The traditional risk factors 
for atherosclerosis differed between patients and controls as 
presented in Table 1. In addition, patients had significantly 
higher CRP levels than HC (8.0 and 2.2, respectively, 
P = 0.0002), even though only patients in clinical remission 
had been selected.
Table 1  Clinical characteristics and risk factors in patients and 
healthy controls
Values are given as mean ± standard deviation or N (%)
BMI Body Mass Index, DM diabetes mellitus, MAP mean arterial 
pressure, HDL high-density lipoprotein, LDL low-density lipoprotein, 
CRP C-reactive protein
a Median (range)
Patients (N = 40) Controls (N = 38) P value
Age, years 56.4 ± 10.5 54.4 ± 9.7 0.38
Male 22 (55) 17 (45) 0.50
Risk factors
 Smoking
  Ever 24 (60) 18 (47) 0.36
  Pack years 13.5 ± 18.1 12.0 ± 18.2 0.53
 BMI 27.8 ± 5.1 25.7 ± 3.6 0.04
 DM 5 (13) 1 (2.6) 0.20
 Current hypertension 23 (58) 8 (21) 0.001
  Systolic 130 ± 18 138 ± 18 0.04
  Diastolic 76 ± 10 82 ± 10 0.01
 MAP 98 ± 12 105 ± 12 0.01
 Total cholesterol 5.85 ± 0.97 5.86 ± 0.99 0.96
  HDL 1.49 ± 0.33 1.55 ± 0.40 0.48
  LDL 3.61 ± 1.01 3.57 ± 0.91 0.85
 Triglycerides 2.09 ± 1.23 1.63 ± 0.87 0.06
 Family history 10 (25) 14 (37) 0.22
 CRP  levela 3.6 (0.37–47.3) 1.1 (0.15–9.5) 0.0002
Table 2  Disease characteristics in ANCA-associated vasculitis
Values are given as median (range) or N (%)
AAV ANCA-associated vasculitis, ANCA antineutrophil cytoplasmic 
antibodies, PR3 proteinase 3, MPO myeloperoxidase, GPA granulo-
matosis with polyangiitis, MPA microscopic polyangiitis
Characteristic AAV (N = 40)









 Churg–Strauss syndrome 4 (10)
 Renal-limited vasculitis 4 (10)
Renal involvement 18 (45)
Cumulative medication
 Prednisolone, g 7.6 (0–80.2)
 Cyclophosphamide, g 18.0 (0–302)
 Azathioprine, g 34.2 (0–303)
Number of relapses 1 (0–5)
Number of patients with relapses 21 (53)
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Median disease duration was 2.6 years (range, 0.6–16.3 
years, Table  2). Twenty-one patients had one or more 
relapses. All but one patient had used prednisolone; 34 
patients had used cyclophosphamide and 36 patients had 
used azathioprine.
Higher percentage of circulating  CD4+CD28null T cells 
in ANCA-associated vasculitis
In patients with AAV, the percentage of circulating 
 CD4+CD28null T cells was significantly higher (median 
3.1%, range 0.01–85) than in HC (median 0.28%, range 
0–36, Table  3). Interestingly, the absolute number of 
 CD4+CD28null T cells did not differ between patients and 
controls (Table  3). Additional FACS analysis showed 
that  CD4+CD28null T cells were CD25 negative, perforin 
positive, and to some extent positive for KIR2DS1 and 
KIR2DS2 (Fig. 1).
CD4+CD28null T cells in AAV are related to anti-CMV 
but not to anti-hHSP60 antibodies
As antigenic specificity of  CD4+CD28null T cells has 
been described to be for hHSP60 and CMV, we deter-
mined the relationship between antibodies against these 
antigens and the presence of  CD4+CD28null T cells. 
Prevalence of antibodies against hHSP60 and CMV was 
comparable between patients and controls (Table  3). 
We could not detect an association between antibod-
ies against hHSP60 and the presence or percentage of 
 CD4+CD28null T cells. However, there was a strong asso-
ciation between a previous CMV infection and the pres-
ence and percentage of  CD4+CD28null T cells (0.33 vs 
13.8, P < 0.001). Interestingly, AAV patients with a previ-
ous CMV infection had a significantly higher percentage 
of  CD4+CD28null T cells than HC with a previous CMV 
infection (Fig.  2). This association was confirmed with 
multiple regression analysis (HC vs ANCA, P = 0.016; 
previous CMV infection, P < 0.0001).
Carotid intima-media thickness is not increased 
in patients with ANCA-associated vasculitis
Both the left and the right common carotid arteries were 
evaluated for the presence of early atherosclerotic damage. 
Results of the IMT measurements are presented in Table 4. 
Patients with AAV did not have a significantly higher IMT 
compared to HC (0.77 ± 0.15 and 0.73 ± 0.11  mm in the 
right CCA, respectively, P = 0.20). As the IMT was not 
always homogenous in patients with AAV, the maximum 
IMT value was additionally determined; these also did not 
differ between patients and controls (Table 4). In multiple 
regression analysis, age (P < 0.001), BMI (P = 0.009), and 
CRP level (P = 0.16) were independent predictors of IMT, 
but AAV was not.
Pulse-wave velocity is increased in patients 
with ANCA-associated vasculitis
To determine vascular elasticity, pulse-wave velocity was 
measured over the carotid-femoral and carotid-radial arte-
rial segments. Since PWV is related to the blood pressure, 
and blood pressure was significantly higher in our HC, we 
corrected PWV in both groups for MAP and compared 
both PWV and MAP-corrected PWV. Femoral PWV was 
comparable between AAV patients and controls, as was 
radial PWV (Table  4). However, when PWV values were 
corrected for MAP, femoral PWV was higher in AAV 
patients (9.77 ± 2.41  m/s, compared to 8.71 ± 1.71  m/s in 
HC, P = 0.04). In addition, radial MAP-corrected PWV was 
higher in patients with AAV (Table 4).
CD4+CD28null cells and previous CMV infection 
not associated with increase in IMT or PWV
We could not detect a difference in IMT between patients 
with >5%  CD4+CD28null T cells and patients with <5%. 
In addition, there was no correlation between IMT and % 
 CD4+CD28null T cells. Furthermore, PWV measurements 
also did not differ between patients with a high or low per-
centage of  CD4+CD28null T cells. In addition, we could not 
detect a difference between patients and controls with or 
without a previous CMV infection.
Table 3  Laboratory evaluation
Values are given as median (range) or N (%)
AAV antineutrophil cytoplasmic-antibody-associated vasculitis, HC 
healthy controls, OR Odds ratio, 95% CI 95% confidence intervals, 
ELISA enzyme-linked immunosorbent assay, anti-hHSP60 antibodies 
against human Heat-Shock Protein 60, anti-CMV antibodies against 
cytomegalovirus
Test AAV patients (N = 40) HC (N = 38) P
Flow cytometry
 %  CD4+CD28null T 
cells
3.1 (0.01–85) 0.3 (0–36) 0.003
 CD4+CD28null cells/
µL
9.8 (0.02–377) 1.5 (0–321) 0.68
ELISA
 Anti-hHSP60 (U/L) 19 (0–256) 18 (0–491) 0.98
 Positive, % 6 (15) 5 (13) 1.0
 Anti-CMV (U/L) 176 (0–250) 5 (0–250) 0.20




In the present study, we determined the presence of early 
atherosclerotic damage, comparing carotid IMT and femo-
ral and radial PWV between AAV patients and healthy age- 
and sex-matched volunteers. No difference in IMT between 
patients and controls was detected. PWV standardized for 
MAP, however, was increased in AAV patients compared 
to healthy controls. Furthermore,  CD4+CD28null T cells 
were found to be present in patients with AAV in a higher 
percentage compared to controls and were found to be 
related to a previous CMV infection. No direct relationship, 
however, between  CD4+CD28null T cells and IMT and/or 
PWV was found.
Patients with AAV who survive the acute phase of their 
vasculitis often die of cardiovascular disease in long-term 
follow-up [8–12]. In addition, patients with AAV have 
a higher incidence of myocardial infarction than their 
background population [13, 14]. The increased incidence 
of myocardial infarction in AAV without an increase in 
IMT and only marginal differences in PWV raises the 
possibility that it is not plaque size but plaque stability 
that may be different between AAV patients and healthy 
subjects. Liuzzo and colleagues reported the presence of 
Fig. 1  FACS analysis of  CD4+CD28null T cells.  CD4+CD28null T 
cells lack expression of CD25 (upper left). On the other hand, they 
are positive for perforin (lower left). Subsets of  CD4+CD28null T cells 
express HLA-Dr (upper right) and CD158b (a marker for killer cell 
immunoglobulin-like receptors, lower right)
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 CD4+CD28null T cells in patients with unstable angina 
or myocardial infarction [23].  CD4+CD28null T cells are 
resistant to apoptosis and the percentage of these cells 
remains remarkably stable during follow-up [32]. Fur-
thermore, these cells are cytotoxic for endothelial cells 
[33] and produce large amounts of interferon γ [33], both 
factors that are relevant for plaque instability. Interest-
ingly, these cells had only invaded the “culprit plaques”, 
i.e., plaques that have ruptured and seemed to have 
caused myocardial infarction. Patients with AAV have 
an increased percentage of circulating  CD4+CD28null T 
cells. Therefore, we postulate that although plaque size 
is comparable between patients and controls, the increase 
in  CD4+CD28null T cells in AAV patients may result in 
an increased propensity for myocardial infarction. It may, 
therefore, be interesting to look at the presence of rup-
ture-prone plaques in patients and controls [34]. In addi-
tion, there may be other factors involved in the occur-
rence of cardiovascular events in AAV patients, such as 
local coronary disease [35] and increased thrombogenic 
risk in patients with AAV [36].
The reason why  CD4+CD28null T cells are relatively 
increased in AAV is not yet clear. Previous studies sug-
gested that hHSP60 and/or CMV may be candidate antigens 
that are recognized by these T cells [24, 25]. In our study, 
we could not detect an association between  CD4+CD28null 
T cells and the presence of anti-hHSP60 antibodies. A pre-
vious CMV infection, however, was highly associated with 
the presence of  CD4+CD28null T cells. The percentage of 
 CD4+CD28null T cells was even higher in AAV patients 
with a previous CMV infection compared to the percent-
age of these cells in healthy controls with a previous CMV 
infection. This may be due to (subclinical) CMV reac-
tivation in AAV patients with a previous CMV infection, 
caused by the immunosuppressive therapy that is needed to 
control active vasculitis. The lack of the CD28 molecule on 
 CD4+CD28null T cells suggests repeated antigenic exposure 
[24], supporting this hypothesis. Interestingly, CMV infec-
tion has been associated with the presence of atherosclero-
sis as well [37]. In mice, CMV infection increases athero-
sclerosis [38].
Treatment with cytostatic therapy with cyclophospha-
mide and/or azathioprine may influence the development 
of atherosclerotic lesions [18, 39]. In patients with chronic 
kidney disease, treatment with immunosuppressive drugs 
had a positive effect on blood pressure and PWV [40]. On 
the other hand, an increase in body weight, hypertension, 
and diabetes mellitus is well-known side effects of the use 
of corticosteroids and also risk factors for developing ath-
erosclerosis. In fact, a study by Wei and colleagues showed 
that chronic use of glucocorticoids is associated with an 
increase of cardiovascular events [41].
This study has some limitations. First, our group of vas-
culitis patients is relatively small, resulting in a low power 
of our study. Second, we used spouses as healthy controls, 
to correct for influences of lifestyle on atherosclerosis. 
This may, however, have resulted in only a small difference 
between our patients and controls. Indeed, in a study by de 
Groot et al. [42], middle-aged healthy controls had an aver-
age carotid IMT of 0.59  mm instead of the 0.73  mm we 
found in our study. Third, although we found a difference in 
PWV between patients and controls, PWV <12 m/s is still 
within the normal range. Fourth, we did not correct for the 
present use of medication or presence of decreased renal 
function, although we did exclude patients who are dialysis 
dependent given that these patients already are at increased 
risk for atherosclerosis [43].
Fig. 2  CD4+CD28null T cells in healthy controls and vasculitis 
patients.  CD4+CD28null T cells are relatively more often present 
in patients with ANCA-associated vasculitis (AAV) who have had 
a cytomegalovirus (CMV) infection (ACMV+). However, they 
are also present in healthy controls with a previous CMV infection 
(HCMV+). In AAV patients and controls without a previous CMV 
infection,  CD4+CD28null T cells are scarcely detected (ACMV− and 
HCMV−, respectively)
Table 4  Vascular tests in patients and healthy controls
All values are mean ± standard deviation
IMT intima-media thickness (mm), PWV pulse-wave velocity (m/s)
Patients Controls P value
IMT
 Right, mean 0.77 ± 0.15 0.73 ± 0.11 0.20
 Right, max 1.027 ± 0.20 0.98 ± 0.13 0.22
 Left, mean 0.73 ± 0.12 0.72 ± 0.11 0.59
 Left, max 0.96 ± 0.18 0.96 ± 0.14 0.99
PWV
 Femoral 9.73 ± 2.76 9.27 ± 2.15 0.44
 Femoral MAP-corrected PWV 9.77 ± 2.41 8.71 ± 1.71 0.04
 Radial 8.85 ± 1.38 8.47 ± 1.88 0.32
 Radial MAP-corrected PWV 8.86 ± 1.41 7.95 ± 1.77 0.02
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In conclusion, we found only minor evidence of accel-
erated atherosclerosis in patients with ANCA-associated 
vasculitis when studying IMT and PWV.  CD4+CD28null T 
cells, however, are relatively increased in AAV and found 
to be related to the previous CMV infection. The occur-
rence of these cells may be relevant for plaque instability 
and responsible for the observed increased incidence of 
myocardial infarction in these patients.
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